---
document_datetime: 2026-01-27 10:21:10
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/mvasi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: mvasi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.397199
conversion_datetime: 2026-01-29 11:53:45.93425
docling_version:
  docling-serve: 1.11.0
  docling-jobkit: 1.9.0
  docling: 2.70.0
  docling-core: 2.61.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## MVASI

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                           |
|----------------------|-------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|---------------------------------------------------|
| Variation type IB /  | C.I.2 Change(s) in the Summary of Product | 26/11/2025                          |                                             | SmPC,                            | To update sections 2, 4.4, and 6.1 of the SmPC to |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000313052          | Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a (Type IB) - To update sections 2, 4.4, and 6.1 of the SmPC to include information on excipient content (Polysorbate 20), based on the Annex to the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use'. The package leaflet is updated accordingly. The implemented changes follow the approval of the same updates to the reference product, Avastin. In addition, the MAH took the opportunity to implement editorial changes throughout the PI to: (1) align with the reference product, (2) align with the QRD template, (3) correct typographic errors, and (4) remove the local representative for UK(NI) in line with the Windsor framework and QRD template.   |            |            | Labelling and PL   | include information on excipient content (Polysorbate 20), based on the Annex to the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use'. The package leaflet is updated accordingly. The implemented changes follow the approval of the same updates to the reference product, Avastin. In addition, the MAH took the opportunity to implement editorial changes throughout the PI to: (1) align with the reference product, (2) align with the QRD template, (3) correct typographic errors, and (4) remove the local representative for UK(NI) in line with the Windsor framework and QRD template.   |
|----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUR / EMA/PSUR/0000274402 | - - In view of available data on hyaline occlusive glomerular microangiopathy reported in the literature, including in some cases a positive                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 16/10/2025 | 19/12/2025 | SmPC               | Variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|                                          | de-challenge and in view of a plausible mechanism of action, the PRAC considers a causal relationship between bevacizumab and hyaline occlusive glomerular microangiopathy is at least a reasonable possibility. The PRAC concluded that the product information of products containing bevacizumab should be amended accordingly.                                                                    |            |     |                 |
|------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------|
| Variation type IA_IN / EMA/VR/0000304407 | This was an application for a group of variations. B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.1 Not including batch control/testing - Accepted B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted | 15/10/2025 |     | Annex II and PL |
| Variation type IB / EMA/VR/0000281362    | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active                                                                                                                          | 09/10/2025 | N/A |                 |

<div style=\"page-break-after: always\"></div>

|                                       | substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.f Changes to quality control testing arrangements for the active substance-replacement or addition of a site where batch control/testing takes place - Accepted                         |            |     |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type II / EMA/VR/0000258406 | B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.c The change refers to a biological / immunological substance or use of a different chemically derived substance in the manufacture of a biological/immunological substance, which may have a significant impact on the quality, safety and efficacy of the medicinal product and is not related to a protocol - Accepted | 05/06/2025 | N/A |